Fig. 2: Viral protein expression levels and virion morphology of rLASV/IGR-CD in vitro. | npj Vaccines

Fig. 2: Viral protein expression levels and virion morphology of rLASV/IGR-CD in vitro.

From: A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs

Fig. 2: Viral protein expression levels and virion morphology of rLASV/IGR-CD in vitro.

A Vero cells or A549 cells were exposed to rLASV-WT or rLASV/IGR-CD and cell lysates were collected at the indicated time points. Western blots were performed on cell lysates with antibodies to LASV NP, LASV GP, or actin beta (loading control). See Supplementary Fig. 4 for uncropped blots. B Resin blocks containing Vero cells infected with rLASV-WT or rLASV/IGR-CD were sectioned and scanned by a transmission electron microscope. Samples contained small quantities of LASV particles measuring 80–140 nm in diameter that were budding from the plasma membranes of infected cells and extracellular mature particles. Shown are two representative images of mature rLASV-WT and rLASV/IGR-CD virus particles in extracellular space of infected Vero cells. CD codon-deoptimized; GP glycoprotein; IGR intergenic region; LASV Lassa virus; MOI multiplicity of infection; NP nucleoprotein; rLASV recombinant LASV; WT wild-type.

Back to article page